We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Telomere Biomarker Blood Test Predicts Cancer Years In Advance

By LabMedica International staff writers
Posted on 12 May 2015
Print article
Image: Telomeres at the end of the chromosomes protecting against DNA deterioration (Photo courtesy of Dr. Joseph Raffaele, MD).
Image: Telomeres at the end of the chromosomes protecting against DNA deterioration (Photo courtesy of Dr. Joseph Raffaele, MD).
Telomeres are sequences of DNA on the ends of chromosomes that stop them fraying and losing their integrity, but they gradually shorten as one ages and by the time one grow up they are half the length they were when a person was born, then they halve again as they enter old age.

Telomeres shorten every time a cell divides, which is why they get progressively shorter as they age and if the telomeres of a cell become too short, they can cause the cell to become faulty, and normally the cell self-destructs. However since cancer cells divide more rapidly than normal cells, the question arises why they do not self-destruct when their telomeres become dangerously short.

Scientists at Northwestern University Feinberg School of Medicine (Chicago, IL, USA) measured telomere length several times over a 13-year period in 792 people. One hundred and thirty-five of the participants eventually developed various cancers, including leukemia, and prostate, skin and lung cancer. The telomeres of the participants who were later diagnosed with cancer aged much faster, that is they shortened more rapidly, in the first few years. In the participants who developed cancer, the telomeres looked as much as 15 years older than those of the participants who did not develop cancer. But what was surprising was that the accelerated aging stopped three to four years before cancer diagnosis.

The authors concluded that relative to approaching cancer diagnosis, age-adjusted blood telomere length (BTL) attrition decelerated in cancer cases, ultimately yielding significantly elongated BTL and suggesting that critical BTL shortening may contribute to cancer initiation which then, in turn, activates telomere maintenance mechanisms to compensate and further promote cancer. These results may help explain the inconsistent results of previous studies and provide more insight into using BTL as an early detection biomarker of cancer.

Lifang Hou, MD, PhD, the lead study author, said, “Understanding this pattern of telomere growth may mean it can be a predictive biomarker for cancer. Because we saw a strong relationship in the pattern across a wide variety of cancers, with the right testing these procedures could be used to eventually diagnose a wide variety of cancers.” The study was published online on the April 30, 2015, in the journal EbioMedicine.

Related Links:

Northwestern University Feinberg School of Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.